RT Journal Article
SR Electronic
T1 Improved diagnosis of SARS-CoV-2 by using Nucleoprotein and Spike protein fragment 2 in quantitative dual ELISA tests
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.07.21255024
DO 10.1101/2021.04.07.21255024
A1 Verissimo, Carolina De M.
A1 O’Brien, Carol
A1 López Corrales, Jesús
A1 Dorey, Amber
A1 Cwiklinski, Krystyna
A1 Lalor, Richard
A1 Doyle, Jack M.
A1 Field, Stephen
A1 Masterson, Claire
A1 Martinez, Eduardo Ribes
A1 Hughes, Gerry
A1 Bergin, Colm
A1 Walshe, Kieran
A1 McNicholas, Bairbre
A1 Laffey, John G.
A1 Dalton, John P.
A1 Kerr, Colm
A1 Doyle, Sean
YR 2021
UL http://medrxiv.org/content/early/2021/04/09/2021.04.07.21255024.abstract
AB The novel Coronavirus, SARS-CoV-2, is the causative agent of the 2020 worldwide coronavirus pandemic. Antibody testing is useful for diagnosing historic infections of a disease in a population. These tests are also a helpful epidemiological tool for predicting how the virus spreads in a community, relating antibody levels to immunity and for assessing herd immunity. In the present study, SARS-CoV-2 viral proteins were recombinantly produced and used to analyse serum from individuals previously exposed, or not, to SARS-CoV-2. The nucleocapsid (Npro) and Spike subunit 2 (S2Frag) proteins were identified as highly immunogenic, although responses to the former were generally greater. These two proteins were used to develop two quantitative ELISA assays that when used in combination resulted in a highly reliable diagnostic test. Npro and S2Frag-ELISAs could detect at least 10% more true positive COVID-19 cases than the commercially available ARCHITECT test (Abbott). Moreover, our quantitative ELISAs also show that specific antibodies to SARS-CoV-2 proteins tend to wane rapidly even in patients that had developed severe disease. As antibody tests complement COVID-19 diagnosis and determine population-level surveillance during this pandemic, the alternative diagnostic we present in this study could play a role in controlling the spread of the virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Science Foundation Ireland (SFI) COVID-19 Rapid Response Funding Call, proposal ID 20/COV/0023 and 20/COV/0048. Mass spectrometry facilities were funded by a Science Foundation Ireland infrastructure award to SD (12/RI/2346(3)).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human experimental work was conducted according to Human Research Ethics Committees. Ethical approval for the healthcare worker serum sample collection and analysis was granted by the St. James's Hospital and Tallaght University Hospital research ethics committee in April 2020 (reference 2020-04 List 15) and permit BSRESC-2020-2403204 (Maynooth University Ethics committee). The work conduced with the samples from hospitalized patients followed the research permit 20-NREC-COV-20 (Galway University hospital research ethics committee). All participants provided written informed consent prior to the study or assent followed by informed consent once able for patients admitted to the ICU where informed consent was not possible.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe supplementary figures (Fig S1 to S4) and table (Table S1) mentioned in the manuscript are available in the Supplementary files uploaded.